GlassScriptPhysician profile
Oscar Pakier
NPI 1447320304
$14,095.58
in general payments reported to CMS, 2019-2025
28 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $814 · 2021: $2,595 · 2022: $1,925 · 2023: $2,561 · 2024: $2,780 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,878 · Education: $55.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,877.61 |
| Education | $55.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,960.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $2,272.12 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,081.93 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $924.03 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $851.62 | 2019-2023 | Spravato |
| Neurocrine Biosciences, INC. | $693.14 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $582.99 | 2019-2023 | Austedo Xr |
| Allergan, INC. | $581.00 | 2019-2020 | |
| Alkermes, INC. | $439.22 | 2022-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $401.19 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $343.04 | 2019 | |
| Vanda Pharmaceuticals INC. | $218.74 | 2019-2024 | Fanapt |
| Tris Pharma INC | $210.70 | 2021 | |
| Sunovion Pharmaceuticals INC. | $179.34 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $173.78 | 2022-2025 | Qelbree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $165.64 | 2020 | |
| Harmony Biosciences LLC | $155.75 | 2021 | |
| Lundbeck LLC | $149.13 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $142.58 | 2023-2025 | Quviviq, Quviviq |
| Novo Nordisk INC | $123.07 | 2024 | |
| Ironshore Pharmaceuticals INC. | $105.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.97 | 2023-2024 | Trintellix |
| Almatica Pharma LLC | $75.20 | 2022-2024 | Loreev Xr |
| Bausch Health US, LLC | $47.03 | 2023 | Wellbutrin, Aplenzin |
| Corium, LLC | $41.55 | 2022 | |
| Jazz Pharmaceuticals INC. | $36.92 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $24.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Pakier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.